Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]-Fluselenamyl PET Imaging for Cardiac Amyloidosis
NCT07771621Phase 1Enrolling by invitation
- Sponsor
- Washington University School of Medicine
- Start
- Jan 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fluselenamyl in cardiac amyloidosis, sponsored by Washington University School of Medicine. Primary endpoint: Cardiac Uptake of [18F]Fluselenamyl at 2 years. Started Jan 2026; status: enrolling by invitation.
02
Drugs
fluselenamyl
03
Conditions
cardiac amyloidosis
Beyond the preview
Go deeper on NCT07771621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07771621.